Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- optimal Ce of remifentanil
研究概览
简要总结
The purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female who are reversed with sugammadex or neostigmine.
详细描述
Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases the at-risk time during extubation. In addition, cough suppression of remifentanil enables smooth extubation with reduced complications. However, the infusion of remifentanil suppresses the emergence cough effectively in clinical practice, whereas it still delays the awakening from anesthesia, resulting in prolonged emergence time. Reduced Ce of remifentanil during emergence would decrease the adverse events that are associated with remifentanil infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 19 Years 至 60 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Laparoscopic cholecystectomy under general anesthesia
排除标准
- •BMI > 30 kg/m2, respiratory infection, uncontrolled hypertension
研究组 & 干预措施
Sugammadex group
Sugammadex group receives the intravenous sugammadex of 2 mg/kg.
干预措施: Sugammadex Injectable Product (Drug)
Neostigmine group
Neostigmine group receives the intravenous neostigmine 50 ug/kg and glycopyrrolate 10 ug/kg.
干预措施: Neostigmine Injectable Product (Drug)
结局指标
主要结局
optimal Ce of remifentanil
时间窗: from the ene of surgery until endotracheal extubation
Using Dixon methods, evaluating of optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia
次要结局
未报告次要终点
研究者
Ji Eun Kim
Associate professor
Ajou University School of Medicine